Advertisement

 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Cardiology

   News

   Conferences

   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links

advertisement.gif (61x7 -- 0 bytes)

   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

     
 
 

 Headlines:

 
 
 
Last Updated: Oct 6, 2008 - 2:59:55 AM

Tekturna - the first new approved antihypertensive in a decade
   
Novartis
Mar 8, 2007 - 8:12:34 AM
Email this article
 Printer friendly page
Novartis announced that the United States has become the first country in the world to approve Tekturna® (aliskiren) tablets, the first new type of medicine in more than a decade for treating high blood pressure - a condition estimated to affect nearly one billion people worldwide and remains uncontrolled in nearly 70% of patients.

The Food and Drug Administration (FDA) issued the approval for Tekturna as the first in a new class of drugs called direct renin inhibitors. A once-daily oral therapy, Tekturna acts by targeting renin - an enzyme responsible for triggering a process that can contribute to high blood pressure. This condition is a leading contributor to cardiovascular disease, considered the world's leading cause of death.

Tekturna received FDA approval for treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. The use of Tekturna with maximal doses of ACE inhibitors has not been adequately studied. Tekturna is expected to be available in March in pharmacies as 150 mg and 300 mg tablets.

"Renin angiotensin system activity contributes to many of the complications associated with high blood pressure," said Marc A. Pfeffer, M.D., PhD, Professor of Medicine, Harvard Medical School and Cardiologist, at Brigham & Women's Hospital. "By inhibiting this important system at its origin, renin production, a direct rennin inhibitor, such as Tekturna, offers an exciting therapeutic option for treating hypertension."

In an extensive clinical trial program involving more than 6,400 patients, Tekturna provided significant blood pressure reductions for a full 24 hours. Furthermore, Tekturna provided added efficacy when used in combination with other commonly used blood pressure medications. In clinical trials, the approved doses of Tekturna were generally well tolerated and the most common side effect experienced by more patients taking Tekturna than patients taking a sugar pill was diarrhea. Other less common reactions to Tekturna include cough and rash.

Tekturna should be discontinued as soon as pregnancy is detected as it may harm an unborn baby, causing injury and even death. Women who plan to become pregnant should talk to their doctor about other treatment options before taking Tekturna.

Angioedema has been rarely reported in patients taking Tekturna.

"Many patients require two or more medicines to control their blood pressure. As a new treatment approach, Tekturna has the potential to help these patients manage their disease," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Tekturna demonstrates our commitment to developing innovative medicines to help the millions of patients suffering from high blood pressure."

Novartis is committed to conducting a large outcome trial program to evaluate the long-term effects of Tekturna and direct renin inhibition.

 
Top of Page

Email this article
Printer friendly page

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright © 2001-2007 The Doctors Lounge. All rights reserved.